Agios Pharmaceuticals' Focus of Drug Research – Cancer Metabolism – Selected for Stand Up To Cancer Grant

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals today announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism “dream team” led by Agios founder Dr. Craig Thompson and including Agios advisors Drs. Chi Dang and Joshua Rabinowitz. Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C’s scientific partner, the American Association for Cancer Research (AACR). Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles’ heel to target this deadly disease.